FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies von Kennedy, Vanessa E., Smith, Catherine C.

Volltext

Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia von Daver, Naval, Perl, Alexander E, Maly, Joseph, Levis, Mark, Ritchie, Ellen, Litzow, Mark, McCloskey, James, Smith, Catherine C, Schiller, Gary, Bradley, Terrence, Tiu, Ramon V, Naqvi, Kiran, Dail, Monique, Brackman, Deanna, Siddani, Satya, Wang, Jing, Chyla, Brenda, Lee, Paul, Altman, Jessica K

Volltext

Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia von Demaree, Benjamin, Delley, Cyrille L., Vasudevan, Harish N., Peretz, Cheryl A. C., Ruff, David, Smith, Catherine C., Abate, Adam R.

Volltext

Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis von Smith, Catherine C., Paguirigan, Amy, Jeschke, Grace R., Lin, Kimberly C., Massi, Evan, Tarver, Theodore, Chin, Chen-Shan, Asthana, Saurabh, Olshen, Adam, Travers, Kevin J., Wang, Susana, Levis, Mark J., Perl, Alexander E., Radich, Jerald P., Shah, Neil P.

Volltext

The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms von Ferng, Timothy T, Terada, Daisuke, Ando, Makoto, Tarver, Theodore C, Chaudhary, Fihr, Lin, Kimberly C, Logan, Aaron C, Smith, Catherine C

Volltext

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor von James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut

Volltext

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD von Smith, Catherine C., Lasater, Elisabeth A., Zhu, Xiaotian, Lin, Kimberly C., Stewart, Whitney K., Damon, Lauren E., Salerno, Sara, Shah, Neil P.

Volltext

Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia von Peretz, Cheryl A. C., Kennedy, Vanessa E., Walia, Anushka, Delley, Cyrille L., Koh, Andrew, Tran, Elaine, Clark, Iain C., Hayford, Corey E., D’Amato, Chris, Xue, Yi, Fontanez, Kristina M., May-Zhang, Aaron A., Smithers, Trinity, Agam, Yigal, Wang, Qian, Dai, Hai-ping, Roy, Ritu, Logan, Aaron C., Perl, Alexander E., Abate, Adam, Olshen, Adam, Smith, Catherine C.

Volltext

The growing landscape of FLT3 inhibition in AML von Smith, Catherine C

Volltext

LNK/ SH2B3 as a novel driver in juvenile myelomonocytic leukemia von Wintering, Astrid, Hecht, Anna, Meyer, Julia, Wong, Eric B, Hübner, Juwita, Abelson, Sydney, Feldman, Kira, Kennedy, Vanessa E, Peretz, Cheryl A C, French, Deborah L, Maguire, Jean Ann, Jobaliya, Chintan, Vasquez, Marta Rojas, Desai, Sunil, Dulman, Robin, Nemecek, Eneida, Haines, Hilary, Hammad, Mahmoud, El Haddad, Alaa, Kogan, Scott C, Abdullaev, Zied, Chehab, Farid F, Tasian, Sarah K, Smith, Catherine C, Loh, Mignon L, Stieglitz, Elliot

Volltext

Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis von Chatterjee, Anindya, Ghosh, Joydeep, Ramdas, Baskar, Mali, Raghuveer Singh, Martin, Holly, Kobayashi, Michihiro, Vemula, Sasidhar, Canela, Victor H., Waskow, Emily R., Visconte, Valeria, Tiu, Ramon V., Smith, Catherine C., Shah, Neil, Bunting, Kevin D., Boswell, H. Scott, Liu, Yan, Chan, Rebecca J., Kapur, Reuben

Volltext

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib von Perl, Alexander E., Hosono, Naoko, Montesinos, Pau, Podoltsev, Nikolai, Martinelli, Giovanni, Panoskaltsis, Nicki, Recher, Christian, Smith, Catherine C., Levis, Mark J., Strickland, Stephen, Röllig, Christoph, Groß-Langenhoff, Marco, Chou, Wen-Chien, Lee, Je-Hwan, Yokoyama, Hisayuki, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon V., Altman, Jessica K.

Volltext

The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment von Tran, Thai Hoa, Nguyen, Jonathan, Stecula, Adrian, Akutagawa, Jon, Moorman, Anthony, Braun, Benjamin S., Sali, Andrej, Mullighan, Charles G., Shah, Neil P., Dai, Yunfeng, Devidas, Meenakshi, Roberts, Kathryn G., Smith, Catherine C., Loh, Mignon L.

Volltext

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor von Verstovsek, Srdan, Tam, Constantine S, Wadleigh, Martha, Sokol, Lubomir, Smith, Catherine C, Bui, Lynne A, Song, Chunyan, Clary, Douglas O, Olszynski, Patrycja, Cortes, Jorge, Kantarjian, Hagop, Shah, Neil P

Volltext

Roman warfare: targeting of support cells in AML von Smith, Catherine C.

Volltext

Isotopic ecology and dietary profiles of Liberian chimpanzees von Smith, Catherine C., Morgan, Michèle E., Pilbeam, David

Volltext

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial von Cortes, Jorge, Perl, Alexander E, Döhner, Hartmut, Kantarjian, Hagop, Martinelli, Giovanni, Kovacsovics, Tibor, Rousselot, Philippe, Steffen, Björn, Dombret, Hervé, Estey, Elihu, Strickland, Stephen, Altman, Jessica K, Baldus, Claudia D, Burnett, Alan, Krämer, Alwin, Russell, Nigel, Shah, Neil P, Smith, Catherine C, Wang, Eunice S, Ifrah, Norbert, Gammon, Guy, Trone, Denise, Lazzaretto, Deborah, Levis, Mark

Volltext

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia von McMahon, Christine M, Ferng, Timothy, Canaani, Jonathan, Wang, Eunice S, Morrissette, Jennifer J D, Eastburn, Dennis J, Pellegrino, Maurizio, Durruthy-Durruthy, Robert, Watt, Christopher D, Asthana, Saurabh, Lasater, Elisabeth A, DeFilippis, RosaAnna, Peretz, Cheryl A C, McGary, Lisa H F, Deihimi, Safoora, Logan, Aaron C, Luger, Selina M, Shah, Neil P, Carroll, Martin, Smith, Catherine C, Perl, Alexander E

Volltext

FLT3 targeting in the modern era: from clonal selection to combination therapies von Kennedy, Vanessa E., Smith, Catherine C.

Volltext

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy von Warkentin, Alexander A, Lopez, Michael S, Lasater, Elisabeth A, Lin, Kimberly, He, Bai-Liang, Leung, Anskar Yh, Smith, Catherine C, Shah, Neil P, Shokat, Kevan M

Volltext